Wednesday, 7 June 2017

AbbVie's rheumatoid arthritis drug succeeds in late-stage trial

(Reuters) - U.S. drugmaker AbbVie Inc said on Wednesday its drug to treat moderate-to-severe rheumatoid arthritis met the main goal in a late-stage study.


Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)